Quantcast
Last updated on April 19, 2014 at 17:21 EDT

Latest Bisphosphonate Stories

2010-09-24 08:15:00

PRAGUE, Sept. 24 /PRNewswire/ -- Enobia Pharma today announced positive results for its Phase II juvenile clinical trial of ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy intended for the treatment of hypophosphatasia (HPP). Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages. Michael Whyte, MD, Medical/Scientific Director of the Center for Metabolic Bone Disease and Molecular Research...

2010-09-03 17:48:50

Research: Oral bisphosphonates and risk of cancer of the esophagus, stomach and colorectum: Case-control analysis within a UK primary care cohort People who take oral bisphosphonates for bone disease over five years may be doubling their risk of developing oesophageal cancer (cancer of the gullet), according to a new study published on bmj.com today. Oral bisphosphonates are a type of drug used to treat osteoporosis and other bone diseases and are the most commonly recommended treatment for...

2010-08-10 23:26:30

Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA. Bisphosphonates are mainly used to prevent or treat osteoporosis, especially in postmenopausal women....

2010-06-05 14:00:00

CHICAGO, June 5 /PRNewswire-USNewswire/ -- Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used to promote bone health and inhibit resorption, may cause a slightly poorer survival rate in post-menopausal women with early stage breast cancer who take them for their anti-osteoporosis properties. The findings were announced today at the 2010 American Society of Clinical Oncology...

2010-06-05 07:27:00

EAST HANOVER, N.J., June 5 /PRNewswire/ -- New data to be presented tomorrow at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, show that the addition of Zometa® (zoledronic acid) to first-line chemotherapy significantly improved overall survival for newly diagnosed multiple myeloma patients by 16% (P=0.0118) and progression-free survival by 12% (P=0.0179) compared with oral clodronate plus first-line chemotherapy(1). The 5.5...

2010-05-26 11:25:00

CHICAGO, May 26 /PRNewswire-USNewswire/ -- People undergoing bisphosphonate therapy to prevent or treat osteoporosis (a thinning of the bones) may be unfamiliar with the drug and possible adverse side effects on oral health, according to a study in the May issue of The Journal of the American Dental Association (JADA). Use of bisphosphonates has been associated with a small risk of developing bisphosphonate-associated osteonecrosis of the jaw (BON) that occurs spontaneously or after the...

2010-03-10 08:55:15

Studies find possible links between prolonged bisphosphonate treatments Bisphosphonate treatments, proven to enhance bone density and reduce fracture incidence in post-menopausal women, may adversely affect bone quality and increase risk of atypical fractures of the femur when used for four or more years, according to preliminary research presented today at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS). Bisphosphonates are designed to slow or stop the bone...

2010-03-10 07:00:00

Studies find possible links between prolonged bisphosphonate treatments and atypical fractures in post-menopausal women NEW ORLEANS, March 10 /PRNewswire-USNewswire/ -- Bisphosphonate treatments, proven to enhance bone density and reduce fracture incidence in post-menopausal women, may adversely affect bone quality and increase risk of atypical fractures of the femur when used for four or more years, according to preliminary research presented today at the 2010 Annual Meeting of the...

2010-03-04 23:00:00

SEATTLE, March 5 /PRNewswire/ -- Women who take some types of bone-building drugs used to prevent and treat osteoporosis may be at lower risk of breast cancer, according to a study by U.S. researchers published today in the British Journal of Cancer. The study found that women who used bisphosphonate drugs, such as Fosamax, Boniva and Zomita, for more than two years had a nearly 40 percent reduction in risk as compared to those who did not, according to lead author Polly Newcomb, Ph.D.,...

2010-03-03 09:11:20

SEATTLE "“ Women who take some types of bone-building drugs used to prevent and treat osteoporosis may be at lower risk of breast cancer, according to a study by U.S. researchers published today in the British Journal of Cancer. The study found that women who used bisphosphonate drugs, such as Fosamax, Boniva and Zomita, for more than two years had a nearly 40 percent reduction in risk as compared to those who did not, according to lead author Polly Newcomb, Ph.D., M.P.H., head of the...